

ASCO congrès 2025

(Légende : **Premier ou Dernier auteur** / **Coauteur Oncopole**)

Hematologic Malignancies—Plasma Cell Dyscrasia

MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial.

Abstract 7500 / Oral Abstract session

Authors : **Aurore Perrot**, Cyrille Hulin, Jerome Lambert, Lionel Karlin, Bertrand Arnulf, Philippe Rey, Laurent Garderet, Margaret Macro, Martine Escoffre Barbe, Julie Gay, Thomas Chalopin, Romain Gounot, Jean Marc Schiano de Colella, Mohamad Mohty, Xavier P. Leleu, Salomon Manier, **Herve Avet-Loiseau**, **Jill Corre**, Philippe Moreau, Cyrille Touzeau

Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial.

Abstract 7501 / Oral Abstract session

Authors : Philippe Moreau, Pieter Sonneveld, Hermann Einsele, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antaonioli, Xavier P. Leleu, Silvia Mangiacavalli, **Aurore Perrot**, Michele Cavo, Angelo Belotti, Annemiek Broijl, Huiling Pei, Anna Sitthi-Amorn, Robin L. Carson, Meletios A. Dimopoulos, Paula Rodríguez-Otero, Mario Boccadoro

First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trisppecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results.

Abstract 7505 / Oral Abstract session

Authors : Niels W. van de Donk, Gala Vega, **Aurore Perrot**, Sébastien Anguille, Albert Oriol, Monique Minnema, Martin F. Kaiser, Hans C. Lee, Alfred Garfall, Jeffrey V. Matous, Larysa J. Sanchez, Azra Borogovac, Lionel Karlin, Saad Z. Usmani, Joseph Weidman, Sangmin Lee, Maria-Victoria Mateos, Paula Rodríguez-Otero, Cyrille Touzeau, Rakesh Popat

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft

QuANTUM-Wild: A phase 3, randomized, double-blind, placebo-controlled trial of quizartinib in combination with chemotherapy and as single-agent maintenance in FLT3-ITD–negative acute myeloid leukemia (AML).

Abstract TPS6580 / Poster Bd 196a / Poster session

Authors : Pau Montesinos, June-Won Cheong, Naval G. Daver, Amir Fathi, Mark J. Levis, Selina M. Luger, Toshihiro Miyamoto, Esther N. Oliva, Alexander E. Perl, **Christian Recher**, Richard F. Schlenk, Jianxiang Wang, Amer M. Zeidan, Li Liu, Yvonne Duong, Karima Imadalou, Karenza Alexis, Akash Nahar, Kristy Burns, Harry P. Erba

Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE).

Abstract 6501 / Oral Abstract Session

Authors : Andreas Hochhaus, François-Xavier Mahon, Tim H. Brümmendorf, Phillipp D. Le Coutre, David J. Andorsky, Susanne Saussele, Stephen Strickland, Thomas Cluzeau, **Françoise Huguet**, Jiří Mayer, Viviane Dubruille, Dong-Wook Kim, Iliana Micheva, Gabrielle Roth Guepin, Virginia Pilipovic, Jacqueline Ryan, Nabil Amirouchene Angelozzi, Nithya Agrawal, Ennan Gu, Delphine Réa

Gastrointestinal Cancer—Colorectal and Anal

Prognostic factors of survival and recurrence after liver transplantation for unresectable colorectal liver metastases: Results from the TransMet trial.

Abstract 3561 / Poster 230 / Poster Session

Authors : Rene Adam, Kawther Nheri, Laurence Chiche, Ephrem Salamé, Olivier Scatton, Victoire Granger, Michel P. Ducreux, Umberto Cillo, Francois Cauchy, Jean-Yves Mabrut, Chris Verslype, Laurent Coubeau, Jean Hardwigsen, Emmanuel Boleslawski, Fabrice Muscari, Jan Lerut, Francis A. Lévi, Maité Lewin, Lamiae Grimaldi, Maximiliano Gelli, TRANSMET Collaborative Study Group

Efficacy and safety of olomorasib, a second-generation KRAS G12C inhibitor, plus cetuximab in KRAS G12C-mutant advanced colorectal cancer.

Abstract 3507 / Oral abstract session

Authors : Antoine Hollebecque, Takafumi Koyama, Yutaka Fujiwara, Yonina R. Murciano-Goroff, Philippe A. Cassier, Natraj R. Ammakkanavar, Dustin A. Deming, **Carlos A. Gomez-Roca**, Sae-Won Han, Mohamedtaki A. Tejani, Anthony B. El-Khoueiry, Nagla F. Abdel Karim, Samantha Bowyer, Victor T. Lin, Samuel McNeely, Xin T. You, Aaron Chen, Aaron A. Fink, Melinda D. Willard, Yasutoshi Kuboki

Immune checkpoint inhibitor (ICI) reuse after failure of first-line ICI in patients with metastatic dMMR/MSI gastrointestinal cancers: The INFLATE study.

Abstract 3569 / Poster session

Authors : Léa Mercier, Filippo Pietrantonio, Edouard Auclin, Michael Overman, Emily Alouani, Antoine Hollebecque, Sara Lonardi, Frank Sinicrope, David Tougeron, Marie Duthelage, Anthony Turpin, Thibault Mazard, Francesco Sclafani, Priya Jayachandran, Javier Ros Montañá, Lola Jade Palmieri, Rosine Guimbaud, Julien Taieb, Simon Pernot

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The Peritoneal Mesotheliomas Cohort.

Abstract TPS4236 / Poster 508b / Poster session

Authors : Julien Peron Sr., Valerie Boige, Pascale Mariani, Clarisse Eveno, Denis M. Smith, Laurence Gladieff, Judith Raimbourg, Nicolas Pirro, Julien Edeline, Marie Viala, Cecile Brigand, Cecile Vicier, Pascale Tomasini, Diego Tosi, Sara Calattini, Sylvie Bin, Fabien Subtil, Benoit You, Vahan Kepenekian

Sarcoma

Advancing precision oncology in soft tissue sarcomas: The role of iTRAC in metastatic risk stratification and treatment personalization.

Abstract 11534 / Poster session

Authors : Fred Chibon, Ataillah Benhaddou, Gaëlle Pérot, Philippe Rochaix, Thibaud Valentin, Gwenael Ferron

Genitourinary Cancer—Prostate, Testicular, and Penile

Treatment of poor-risk non seminomatous germ-cell tumors (NSGCT) adapted by tumor marker decline: A 7-year multicenter real-world experience.

Abstract 5034 / Poster Session

Authors : Sara Faouzi, Leonor Chaltiel, Natacha Naoun, Marion Rolland, Clement Dumont, Marine Gross-Goupil, Lionnel Geoffrois, Emmanuelle Bompas, Brigitte Laguerre, Guilhem Roubaud, Magalie Tardy, Aude Flechon, Constance Thibault, Diego Tosi, Hakim Mahammedi, Christine Chevreau, Karim Fizazi, Damien Pouessel

Breast Cancer—Metastatic

Efficacy of tucatinib, trastuzumab, and capecitabine (TTC) following trastuzumab-deruxtecan (T-DXd) in HER2-positive metastatic breast cancer (MBC): Updated results and subgroup analyses from the UNICANCER multicenter retrospective cohort.

Abstract 1030 / Poster Bd 9 / Poster Sessions

Authors : Jean-Sebastien Frenel, Jean Zeghondy, Catherine Guerin, Audrey Mailliez, Elsa Volant, Francois Poumeaud, Anne Patsouris, Monica Arnedos, Caroline Bailleux, Fanny Le Du, Loik Galland, Alexandre de Nonneville, Severine Guiu Lahaye, Barbara Pistilli, Florence Dalenc, Thomas Bachelot, Jean-Yves Pierga, Louis Larrouquere, Delphine Loirat

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Assessment of homologous recombination deficiency and BRCA status in ovarian cancer: Analytical performance and relevance of a decentralized NGS assay for comprehensive genomic profiling.

Abstract 3130 / Poster Bd 445 / Poster session

Authors : Mohit Gupta, Michael Rozas, Vinay K. Mittal, Xiaoping Duan, Michael Allen, Cheng-Zong Bai, Jim Veitch, José Luis Costa, Philip Jermann, Seth Sadis, Elaine Wong-Ho, Luca Quagliata, Julia Welz, Domenica Lorusso, Maria Jesús Rubio-Pérez, Regina Berger, Sakari Hietanen, Guillaume Bataillon, Eric Pujade-Lauraine, Isabelle L. Ray-Coquard

Trial in progress: First-in-human study of PFL-721/STX-721 in participants with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations.

Abstract TPS3173 / Poster Bd 480a / Poster session

Authors : Anas Gazzah, Chia-Chi Lin, Gerrina Ruiters, Pilar Garrido, Julien Mazieres, Enriqueta Felip, Yung-Hung Luo, David R. Spigel, Sandrine Huret, Ki Hyeong Lee, Allegra Mondillo, Marie Bernardo, Ming Lin, Bill Bradley, Simon Roberts, Raymond Pagliarini, Jin Xu, Mark Chao, Danny Nguyen, Alex Spira

IMMUNONET: A multicenter, open-label, proof-of-concept phase II trial evaluating NP137 as add-on therapy in advanced/metastatic solid tumors treated with standard immunotherapies.

Abstract TPS3177 / Poster Bd 482a / Poster session

Authors : Jérôme Fayette, Eve-Marie Neidhardt, Victoria Ferrari, Mona Amini Adle, Jean-Pierre Delord, David Pérol, Gwenaëlle Garin, Camille Schiffler, Stephane Depil, Nerea Muñoz Unceta, Elise Georges, Esmá Saada

Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Efficacy and safety of nivolumab plus ipilimumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial.

Abstract 8016 / Rapid oral Abstract session

Authors : Nicolas Girard, Benjamin Besse, Michaël Duruisseaux, Laurent Greillier, Thierry Berghmans, Nuria Pardo, Sanjay Papat, Radj Gervais, Santiago Ponce Aix, Annelies Janssens, Sjaak Burgers, Joachim Aerts, **Julien Mazieres**, Yvonne J. Summers, Anne-Claire Toffart, Anne-sophie Govaerts, Eleni Xenophontos, Luc Boone, Solange Peters

IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The B3 Thymomas and Thymic Carcinomas Cohort.

Abstract TPS8130 / Poster session

Authors : Michaël Duruisseaux, Benjamin Besse, Nicolas Girard, Eric Dansin, Sophie Cousin, **Julien Mazieres**, Ludovic Doucet, Anne Madroszyk, Laurent Greillier, Charles Ricordel, Sarah Cavaillon, Celine Mascaux, Cécile Vicier, Diego Tosi, Sara Calattini, Vérane Schwiertz, Sylvie Bin, Fabien Subtil, Benoit You, Thomas Pierret

Lung Cancer—Non-Small Cell Metastatic

A phase 2 safety and efficacy study of PRT3789 in combination with pembrolizumab in patients with advanced or metastatic solid tumors and a SMARCA4 mutation.

Abstract TPS8667 / Poster 137a / Poster session

Authors : Timothy A. Yap, Martin Gutierrez, Wade T. Iams, Victor Moreno, Tatiana Hernandez Guerrero, Guzman Alonso, **Carlos A. Gomez-Roca**, Sophie Postel-Vinay, Fabian Acker, Anna R. Minchom, Natasha B. Leighl, William F. Novotny, Chris Tankersley, Megan Henry, Sunhee Ro, Michael J. Chisamore, John Bridgewater

Evaluation of the combination of regorafenib + avelumab in patients with non-small cell lung cancer without oncogenic addiction: The phase II REGOMUNE study.

Abstract 8549 / Poster 29 / Poster session

Authors : Sophie Cousin, Carine A. Bellera, Jean Philippe Guégan, Quentin Thomas, **Iphigenie Korakis**, Jean-Philippe Metges, Fanny Bouteiller, Michèle Kind, Laura Leroy, Xavier Quantin, Isabelle Soubeyran, Alban Bessede, Antoine Italiano

Central Nervous System Tumors

A phase 2 study of pemigatinib for pre-treated glioblastoma or other gliomas with activating FGFR1-3 alterations: Results from FIGHT-209.

Abstract 2003 / Oral abstract session

Authors : Enrico Franceschi, Martin J. Van Den Bent, Marc Sanson, Andrew B. Lassman, Giuseppe Lombardi, Maria Vieito Villar, Roy E. Strowd, Juan Manuel Sepulveda Sanchez,



INSTITUT UNIVERSITAIRE
DU CANCER DE TOULOUSE
Oncopole

Catherine McBain, Rikke H. Dahlrot, Estela Pineda, **Delphine Larrieu**, Alessia Pellerino, Yoshitaka Narita, Stephen J. Bagley, Lalanthica Yogendran, Natalia Oliveira, Yufei Guo, Louis Viviers, Manmeet S. Ahluwalia

Developmental Therapeutics—Immunotherapy

EXPAND-1, a phase I/II study with ANV600, a novel PD-1 targeted IL-2R- $\beta\gamma$ agonist, in monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors.

Abstract TPS2701 / Poster 331b / Poster session

Authors : **Iphigenie Korakis**, Martina Imbimbo, Emiliano Calvo, Sebastian Ochsenreither, Ignacio Ortego, Pascale Tomasini, Kaïssa Ouali, Alexander Desuki, Daniela Di Blasi, Eduard Gasal, Markus Joerger

Randomized phase II trial evaluating the combination of TG4001, an HPV16 therapeutic vaccine, and avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic (R/M) HPV16-positive cervical or anogenital cancer.

Abstract 2638 / Poster Bd 285 / Poster session

Authors : *Christophe Le Tourneau*, Frederic Rolland, Olivier Capitain, Philippe A. Cassier, Jean David Fumet, Sebastien Salas, Amaury Daste, Luis Manso, Maria-Jose Bermejo-Perez, Antonio Casado, Laura Mansi, Patricia Pautier, Olivier Lantz, Emmanuelle Dochy, Clémentine Spring-Giusti, Katell Bidet Huang, Hakim Makhloufi, Céline Halluard, Annette Tavernaro, **Jean-Pierre Delord**

IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The Anaplastic Thyroid Carcinomas Cohort.

Abstract TPS2693 / Poster session

Authors : Hélène Lasolle, Julien Hadoux, Segolene Hescot, Arnaud Jannin, Yann Godbert, **Victor Sarradin**, Alexandre Lugat, Patricia Niccoli, Marie-Eve Garcia, Marie Vinches, Mickael Burgy, Cécile Vicier, Pascale Tomasini, Diego Tosi, Sara Calattini, Sylvie Bin, Fabien Subtil, Benoit You, Marie Béguinot

Plenary Session

NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.

Abstract LBA2 / Abstract presentation 2 / Plenary sessions

Authors : Jean Bourhis, Anne Auperin, Christian Borel, Gautier Lefebvre, Severine Racadot, Lionnel Geoffrois, Xu Shan Sun, Esma Saada, Beatriz Cirauqui, Tomasz Rutkowski, Stephanie Henry, Anouchka Modesto, Alison Johnson, Benoit Calderon, Yoann Pointreau, Elisabeth Perez Ruiz, Joanna Kazmierska, Amanda Psyri, Ricard Mesia, Yungan Tao, GORTEC

Head and Neck Cancer

Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT).

Abstract 6000 / Oral abstract session

Authors : Shlomo A. Koyfman, Jenny H. Lee, Laurent Mortier, Åse Bratland, Noel E. Luna-Romero, Mitchell Chipman, Marcin Dzienis, Mikhail Klochikhin, Jeremy Long, Dmitry Kirtbaya, Marcus Monroe, Markus A. Gifoni, John M. Kaczmar, Jennifer DeSimone, Angela R. Zambrano, Cecile Pages Laurent, Juan Shen, Jianda Yuan, Burak Gumuscu, Michael Schenker

Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC).

Abstract 6013 / Rapid oral abstract session

Authors : Yungan Tao, Lillian L. Siu, Lisa F. Licitra, Barbara Burtness, Makoto Tahara, Danny Rischin, Gustavo V. Alves, Iane Pinto Figueiredo Lima, Brett G. Hughes, Yoann Pointreau, Sercan Aksoy, Simon Laban, Richard Greil, Martin Burian, Marcin Hetnał, Jean-Pierre Delord, Laurent Kassalow, Behzad Bidadi, Burak Gumuscu, Jean-Pascal H. Machiels

Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts).

Abstract 6016 / Rapid oral abstract session

Authors : Christophe Le Tourneau, Jean-Pierre Delord, Olivier Lantz, Emmanuelle Dochy, Maurizio Ceppi, Clémentine Spring-Giusti, Katell Bidet Huang, Berangere Bastien, Annette Tavernaro, Gisele Lacoste, Per Brattas, Allan Devanadera, Hugues Fontenelle, Oliver Baker, Andrea Meiser, Christian H. Ottensmeier

Gynecologic Cancer

SALVOVAR: A pragmatic randomized phase III trial comparing the salvage weekly dose-dense regimen to the standard 3-weekly regimen in patients with poor prognostic ovarian cancers (GINECO-OV130b; ENGOT-ov78).

Abstract TPS5626 / Poster 520a / Poster session

Authors : Benoit You, Nozomu Yanaihara, Gabriella Parma, Sylvie Chabaud, Laura Del Carpio, Andrew R. Clamp, Gwenael Ferron, Judith R. Kroep, Alexandra Leary, David Cibula, Frédéric Fiteni, Ilan Bruchim, Hassan Serrier, Susannah Catherine Carroll, Anne-Sophie Belmont, Julien Peron Sr., Claire Chator

IMMUNORARE5: A national platform of 5 academic phase II trials coordinated by Lyon University Hospital to assess the safety and the efficacy of the immunotherapy with domvanalimab + zimberelimab combination in patients with advanced rare cancers—The Gestational Trophoblastic Tumors Cohort.

Abstract TPS5636 / Poster 525a / Poster session

Authors : Benoit You, Alexandra Leary, Mathieu Jamelot, Pauline Parent, Coriolan Lebreton, Laurence Gladieff, Jean-Sebastien Frenel, Magali Provansal, Marie Meurer, Thibault De La Motte Rouge, Veronique D'hondt, Lauriane Eberst, Cecile Vicier, Pascale Tomasini, Diego Tosi, Sara Calattini, Touria Hajri, Vêrane Schwiertz, Fabien Subtil, Pierre-Adrien Bolze

ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72).

Abstract LBA5507 / Oral abstract session

Authors : Alexander Olawaiye, Laurence Gladieff, Lucy Gilbert, Jae-Weon Kim, Mariana Scaranti, Vanda Salutari, Elizabeth Hopp, Linda R. Mileskin, Alix Devaux, Michael McCollum, Ana Oaknin, Aliza L. Leiser, Nicoletta Colombo, Andrew R. Clamp, Boglarka Balazs, Giuseppa Scandurra, Emilie Kaczmarek, Hristina I. Pashova, Sachin G. Pai, Domenica Lorusso

Online publications

Omission of elective neck irradiation in pT3-T4 oral squamous cell carcinoma with a pN0 neck: Impact on regional control and overall survival.

Abstract e18091 / Online publication

Authors : Mathilde Mirallié, Anouchka Modesto, Marie-Christelle Pajiep, Jean-Pierre Delord, Sébastien Vergez, Lucie Piram, Céline Dalmasso, Emilien Chabrilac, Agnès Dupret-Bories

PROPAN: Bayesian dose-finding of propranolol combined with metronomic fixed-dose cyclophosphamide based on bivariate efficacy-tolerability outcomes in patients with locally advanced or metastatic angiosarcoma (LAMA): A phase I-II sequential trial by the French Sarcoma Group.

Abstract e23542 / Online publication



INSTITUT UNIVERSITAIRE
DU CANCER DE TOULOUSE
Oncopole

Authors : Sebastien Salas, **Christine Chevreau**, Elisabeth Jouve, Nicolas Penel, Axel Le Cesne, Emmanuelle Bompas, Francois Bertucci, Jean Emmanuel Kurtz, Nicolas Isambert, Loic Chaigneau, Joelle Micallef, EVA Foinet Jr., Nicolas Andre, Sarah Zohar, Jean-Yves Blay